People in India are still wary of organ transplants. So, there is an urgent need of increased public awareness.
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
First and only PARP inhibitor to improve invasive disease-free survival in patients
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Subscribe To Our Newsletter & Stay Updated
